Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22365006 | 0.94 | BRAF (0.89) | BRAFFYN | |
| SCHEMBL22365005 | 0.92 | BRAF (0.84) | BRAFFYN | |
| SCHEMBL12857681 | 0.90 | BRAF (0.85) | BRAF | |
| SCHEMBL1121951 | 0.90 | BRAF (1.00) | BRAF | |
| SCHEMBL1122350 | 0.89 | BRAF (0.80) | BRAF | |
| SCHEMBL1122550 | 0.88 | BRAF (0.81) | BRAF | |
| SCHEMBL1122477 | 0.88 | BRAF (0.79) | BRAF | |
| SCHEMBL1122352 | 0.88 | BRAF (1.00) | BRAFFYN | |
| SCHEMBL1122545 | 0.87 | BRAF (1.00) | BRAFFYN | |
| SCHEMBL12857879 | 0.87 | BRAF (0.77) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
| EP-4108248-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-1831184-B1 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | WELLCOME TRUST LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| EP-1831184-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | The Wellcome Trust Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067466-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | THE WELLCOME TRUST LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | KRAS, BRAF, NRAS | BRAF 2/4885FYN 929/4885 |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885FYN 691/4885 |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | BRAF 224/4885FYN 898/4885 |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BRAF, NRAS, KRAS | BRAF 1/4885FYN 693/4885 |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | BRAF, RAF1, BCOR | BRAF 1/4885FYN 2342/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885FYN 691/4885 |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | BRAF 478/4885FYN 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.